RESUMO
OBJECTIVE: Studies have shown that weekly bisphosphonate dosing results in improved persistence compared to daily dosing among patients with postmenopausal osteoporosis, yet more than 50% of patients discontinue therapy within a year. An oral, less frequent administration bisphosphonate provides an opportunity to improve persistence, a parameter not well modeled in previous cost-effectiveness analyses of osteoporosis therapies. RESEARCH DESIGN AND METHODS: We developed a Markov model to estimate the effect of improved persistence on the cost-effectiveness of bisphosphonates among postmenopausal women with established osteoporosis (vertebral fracture and bone mineral density T-score Assuntos
Análise Custo-Benefício
, Difosfonatos/uso terapêutico
, Osteoporose/tratamento farmacológico
, Pós-Menopausa
, Administração Oral
, Densidade Óssea
, Estudos de Coortes
, Difosfonatos/administração & dosagem
, Feminino
, Fraturas Ósseas/etiologia
, Humanos
, Cadeias de Markov
, Pessoa de Meia-Idade
, Osteoporose/complicações
, Anos de Vida Ajustados por Qualidade de Vida
, Fatores de Risco